Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors

BACKGROUND: Metastatic uveal melanoma (MUM) is associated with poor survival and inferior response to immune checkpoint inhibitor (ICI) therapy when compared with metastatic cutaneous melanoma. Currently, prognostic biomarkers are lacking to guide treatment decisions. PATIENTS AND METHODS: We conduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sander, Michael S., Stukalin, Igor, Vallerand, Isabelle A., Goutam, Siddhartha, Ewanchuk, Benjamin W., Meyers, Daniel E., Pabani, Aliyah, Morris, Don G., Heng, Daniel Y. C., Cheng, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026925/
https://www.ncbi.nlm.nih.gov/pubmed/33724676
http://dx.doi.org/10.1002/cam4.3784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026925/
https://www.ncbi.nlm.nih.gov/pubmed/33724676
http://dx.doi.org/10.1002/cam4.3784

Ejemplares similares